COSCIENS Biopharma Inc.【CSCIF】

Market cap

$87.12M

P/E ratio

	Dec 31, 2017	Dec 31, 2018	Dec 31, 2019	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024
Net Income (loss)	-17	4	-6	-5	-8	-23	-17	-15
Depreciation and amortization	-	-	0	0	0	0	0	2
Share-based compensation costs	0	1	1	0	0	1	0	0
Impairment of intangible assets (note 12)	-	-	-	-	-	-	-	3
Impairment of property and equipment (note 11)	-	-	-	-	-	-	-	1
Employee future benefits	-	-	-	-	0	0	1	0
Amortization of deferred revenues	-	-	-	-	2	-2	-2	-1
Change in fair value of warrant and DSU liabilities	-	-	-	-	-	-	-	-3
Other non-cash items	-0	0	-0	0	0	-	-	0
Income tax (recovery) expense	-	-	-	-	-	-	-	0
Changes in operating assets and liabilities (note 20)	2	0	2	-2	-	1	1	3
Net cash provided by (used in) operating activities	-23	7	-11	-4	-9	-14	-17	-15
Payments on exercise of DSUs	-	-	-	-	-	-	-	0
Payments on lease liabilities	-	-	1	0	0	0	0	0
Net cash used in financing activities	8	-	4	20	51	-0	-0	-1
Cash acquired on acquisition of Aeterna Zentaris Inc. (note 5)	-	-	-	-	-	-	-	26
Purchase of property and equipment	0	0	-	-	0	0	0	1
Changes in restricted cash equivalents	0	-0	0	0	-0	-0	-0	0
Net cash provided by (used in) investing activities	0	-0	0	0	-1	-0	1	25
Effect of exchange rate changes on cash and cash equivalents	0	-0	0	0	-1	-1	0	-0
Net change in cash and cash equivalents	-14	7	-7	16	41	-15	-17	10